Major Discussions on Lennox-Gastaut Syndrome at Upcoming Meeting
From December 6-10, this year's American Epilepsy Society Annual Meeting will shine a spotlight on Lennox-Gastaut Syndrome (LGS). This condition is gaining significant attention due to increased awareness and promising research outcomes.
Insights from Leading Experts
Attendees will have the opportunity to hear from distinguished speakers, including Dr. Tracy Dixon-Salazar, who has been instrumental in advocating for those affected by LGS. Experts will share the latest advancements in research, treatment, and support for patients and families dealing with this complex syndrome.
Schedule of Key Presentations
Dr. Dixon-Salazar will lead several critical discussions during the meeting:
- Friday, Dec. 6 at 6:00 pm: Exploring the Complexities of LGS in Adults, focusing on Seizures and Caregiver Support.
- Sunday, Dec. 8 at 2:05 pm: Engaging Debate on whether LGS should be treated as a dynamic diagnosis.
- Sunday, Dec. 8 at 3:15 pm: Workshop on Expanding Access to Innovative Therapies for Patients through Clinical Trials.
Engagement Opportunities
Also during the meeting:
- Thursday, Dec. 5 at 7:30 pm: Special screening of the musical It's All Your Fault, Tyler Price! at The Hudson Theatre.
- Saturday, Dec. 7 - Monday, Dec. 9: Meet representatives at the LGS Foundation's booth N2148 in the Epilepsy Resource Area.
- Saturday, Dec. 7 at 2:30 pm: Symposium focused on pioneering Treatment and Prevention strategies for LGS.
- Sunday, Dec. 8 at 10:30 am: Workshop on whether treatment strategies for Generalized Epilepsy should be syndrome-specific or general.
About Lennox-Gastaut Syndrome
Lennox-Gastaut Syndrome is a severe and life-threatening form of epilepsy that typically emerges in childhood. It manifests as frequent seizures, cognitive impairment, and potential lifelong disabilities. Currently, there is no cure for LGS, making ongoing research and advocacy critical.
Advocacy and Research Initiatives
Dr. Dixon-Salazar emphasizes the urgent need for improved treatment approaches after decades of limited progress: "LGS management needs a new perspective, as current treatments often fail to control seizures in patients adequately.”
The LGS Foundation, under the guidance of Scientific Director Dr. Mike McConnell, is launching a pivotal study aimed at understanding the natural history of LGS, which will gather data to inform better treatment strategies and enhance the lives of patients and their families.
With an investment of over $1.8 million in research over the past 15 years, the Foundation's programs have funded numerous projects crosswise various nations with priorities set for streaming ahead in research focused on sleep, communication, and seizure patterns to further LGS understanding.
About the LGS Foundation
The LGS Foundation aims to improve the quality of life for those affected by Lennox-Gastaut Syndrome. Through their efforts in advancing research, raising awareness, and providing education and family support, they strive to bring hope and relief to the LGS community.
Frequently Asked Questions
What is Lennox-Gastaut Syndrome?
Lennox-Gastaut Syndrome is a severe epilepsy condition that typically appears in childhood, characterized by frequent seizures and cognitive decline.
Who are the keynote speakers at the meeting?
Dr. Tracy Dixon-Salazar and other leading experts will present at the American Epilepsy Society Annual Meeting to discuss advancements in LGS.
What are some important sessions to attend?
Notable sessions include discussions on adult LGS complexities, treatment debates, and workshops focused on improving access to new therapies.
How much has the LGS Foundation invested in research?
The LGS Foundation has invested over $1.8 million into research initiatives over the last 15 years to understand and treat LGS more effectively.
How does the LGS Foundation support the community?
The Foundation provides resources for research, education, awareness, and family support to improve the lives of individuals impacted by LGS.
